Core Laboratories director awarded 7,895 restricted shares
Core Laboratories director Martha Z. Carnes reported equity compensation activity involving restricted shares and common stock.
Rhea-AI Filing Summary
Core Laboratories director Martha Z. Carnes reported equity compensation activity involving restricted shares and common stock. She received a grant of 7,895 Restricted Shares on April 1, 2026, which will vest after a one-year vesting period ending April 1, 2027, subject to the terms of issuance.
On the same date, 8,069 previously granted Restricted Shares completed their one-year vesting period ending April 1, 2026 and were converted into 8,069 shares of Common Stock at no cash exercise price. Following these transactions, she directly holds 54,397 shares of Core Laboratories common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
8,069 shares exercised/converted
Exercise
3 txns
Insider
Carnes Martha Z.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Shares | 7,895 | $0.00 | $0.00 |
| Exercise | Restricted Shares | 8,069 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,069 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Shares — 7,895 contracts (Direct);
Common Stock — 54,397 shares (Direct)
Footnotes (2)
- F1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board.
- F2. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.
Key Figures
Restricted Share Grant: 7,895 Restricted Shares
Vested Restricted Shares: 8,069 Restricted Shares
Common Stock Acquired: 8,069 shares
+2 more
5 metrics
Restricted Share Grant
7,895 Restricted Shares
Granted April 1, 2026; one-year vesting period to April 1, 2027
Vested Restricted Shares
8,069 Restricted Shares
Vested after one-year vesting period ending April 1, 2026
Common Stock Acquired
8,069 shares
Common Stock received from conversion of vested Restricted Shares at $0.00 per share
Post-transaction holdings
54,397 Common Shares
Direct ownership after Form 4 transactions
Transaction price per share
$0.00 per share
Reported for Restricted Shares and Common Stock in these transactions
Key Terms
Restricted Shares, vesting period, deferral election, Treasury Regulation 1.409A-2, +1 more
5 terms
vesting period financial
"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027"
A vesting period is the set amount of time someone must wait before they fully own granted shares, stock options, or other equity tied to their work or an agreement; ownership increases gradually or in steps during that time. Investors care because vesting determines when insiders or employees can sell shares, which affects future supply of stock, company incentives and executive retention—think of it like unlocking ownership over installments rather than receiving it all at once.
deferral election financial
"Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2"
Treasury Regulation 1.409A-2 financial
"subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2"
separation of service financial
"the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Core Laboratories (CLB) director Martha Carnes report?
Martha Z. Carnes reported equity compensation activity, not open-market trades. She received 7,895 Restricted Shares and saw 8,069 previously granted Restricted Shares vest into Common Stock, all at a transaction price of $0.00 per share as part of her director compensation.
Were there any open-market buys or sells by Martha Carnes in this Core Laboratories Form 4?
No open-market purchases or sales were reported. The Form 4 shows only equity compensation-related activity: a grant of 7,895 Restricted Shares and the vesting and conversion of 8,069 Restricted Shares into Common Stock, all at a transaction price of $0.00 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
